MariTide Research: What 15 Studies Show (2026) | RetatrutideCompare

MariTide — 15 studies indexed on PubMed. GIPR antagonism plus GLP-1R agonism delivered as a single antibody-peptide conjugate. Monthly subcutaneous dosing. Half-life: ~21 days. FDA status: Investigational (Phase 3 MARITIME).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on MariTide?

There are approximately 15 studies indexed on PubMed that mention MariTide (AMG 133, Maridebart cafraglutide), based on a search last updated 2026-06-18.

Is MariTide FDA-approved?

FDA status: Investigational (Phase 3 MARITIME).

How does MariTide work?

GIPR antagonism plus GLP-1R agonism delivered as a single antibody-peptide conjugate. Monthly subcutaneous dosing.

GIPR antagonism plus GLP-1R agonism delivered as a single antibody-peptide conjugate. Monthly subcutaneous dosing.

Reference facts

Also known as
AMG 133, Maridebart cafraglutide
Category
GLP-1 & Metabolic
Mechanism of action
GIPR antagonism plus GLP-1R agonism delivered as a single antibody-peptide conjugate. Monthly subcutaneous dosing.
Targets
GIPR (antagonist), GLP-1R (agonist)
Indications under research or approved
Obesity, Type 2 Diabetes
Regulatory status (reference entry)
Investigational (Phase 3 MARITIME)
Half-life
~21 days
Sequence notes
Peptide-antibody conjugate: monoclonal anti-GIPR antibody covalently linked to two GLP-1 analog peptides via stable conjugation.
Molecular weight (Da)
150000
Originator / sponsor
Amgen
First reported
2023

Primary References

Explore research articles about MariTide

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.